Betta Pharmaceuticals Co Ltd
SZSE:300558
Intrinsic Value
Betta Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of anticancer targeted drugs. [ Read More ]
The intrinsic value of one Betta Pharmaceuticals Co Ltd stock under the Base Case scenario is 27.27 CNY. Compared to the current market price of 42.84 CNY, Betta Pharmaceuticals Co Ltd is Overvalued by 36%.
Valuation Backtest
Betta Pharmaceuticals Co Ltd
Run backtest to discover the historical profit from buying and selling Betta Pharmaceuticals Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Betta Pharmaceuticals Co Ltd
| Current Assets | 1.5B |
| Cash & Short-Term Investments | 752.5m |
| Receivables | 429.2m |
| Other Current Assets | 344.1m |
| Non-Current Assets | 7.6B |
| Long-Term Investments | 1.4B |
| PP&E | 2.6B |
| Intangibles | 3.6B |
| Other Non-Current Assets | 39.1m |
| Current Liabilities | 1.8B |
| Accounts Payable | 800.1m |
| Accrued Liabilities | 363.5m |
| Short-Term Debt | 300m |
| Other Current Liabilities | 339.5m |
| Non-Current Liabilities | 2.1B |
| Long-Term Debt | 1.8B |
| Other Non-Current Liabilities | 268.5m |
Earnings Waterfall
Betta Pharmaceuticals Co Ltd
|
Revenue
|
2.7B
CNY
|
|
Cost of Revenue
|
-470.1m
CNY
|
|
Gross Profit
|
2.2B
CNY
|
|
Operating Expenses
|
-1.8B
CNY
|
|
Operating Income
|
421.7m
CNY
|
|
Other Expenses
|
-26.9m
CNY
|
|
Net Income
|
394.8m
CNY
|
Free Cash Flow Analysis
Betta Pharmaceuticals Co Ltd
Profitability Score
Profitability Due Diligence
Betta Pharmaceuticals Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Betta Pharmaceuticals Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Betta Pharmaceuticals Co Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Betta Pharmaceuticals Co Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Betta Pharmaceuticals Co Ltd
According to Wall Street analysts, the average 1-year price target for Betta Pharmaceuticals Co Ltd is 51.99 CNY with a low forecast of 42.37 CNY and a high forecast of 63 CNY.
Shareholder Return
Price
Betta Pharmaceuticals Co Ltd
| Average Annual Return | 16.02% |
| Standard Deviation of Annual Returns | 53.29% |
| Max Drawdown | -77% |
| Market Capitalization | 17.9B CNY |
| Shares Outstanding | 418 485 885 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Betta Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of anticancer targeted drugs. The company is headquartered in Hangzhou, Zhejiang and currently employs 1,677 full-time employees. The company went IPO on 2016-11-07. The firm's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The firm is also engaged in promotional services, real estate leasing and other businesses.
Contact
IPO
Employees
Officers
The intrinsic value of one Betta Pharmaceuticals Co Ltd stock under the Base Case scenario is 27.27 CNY.
Compared to the current market price of 42.84 CNY, Betta Pharmaceuticals Co Ltd is Overvalued by 36%.
You don't have any saved screeners yet
